Xencor Inc (XNCR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$26.61-0.04%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · XNCR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -1.7% |
| Our one-year growth estimate | diamond | 13.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 15.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
XNCR — earnings miss
Dated 2026-05-06
Results of Operations and Financial Condition” of this Current Report on Form 8-K and in Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly s…
Why it matters: Progress in this study is key for Xencor's rheumatoid arthritis treatments.
Supportive ifPositive update on progress from the Phase 1b study of Plamotamab in 2H26.
Worry ifNo update or negative results from the Phase 1b study.
Why it matters: Better cash flow is key for funding research. A good update could help investors feel better.
Supportive ifCash flow from operations improves from -$67.63M in 2026-Q1.
Worry ifCash flow from operations worsens or remains negative.
Why it matters: Updates on cash could affect funding for current and future clinical trials.
Supportive ifXencor receives the first $52.5 million payment from Alexion as part of the settlement.
Worry ifCash balance does not improve. It may drop a lot after the settlement.
Why it matters: Higher revenue growth shows success in making more money. This is very important.
Supportive ifQ2 revenue grows year over year by more than 5%.
Worry ifQ2 revenue growth is less than 5% year over year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$250 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $585 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,261 loss on $10,000 · 42.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Worsening cash flow indicates deeper financial issues. It shows the company is struggling to manage its costs.
Worry ifCash flow from operations worsens beyond -$67.6M in Q2.
Less concerning ifCash flow from operations improves to less negative than -$67.6M in Q2.
Why it matters: An updated financial outlook will clarify the impact of the earnings miss on cash flow.
Worry ifManagement will share a new cash flow outlook after the earnings miss on August 5, 2026.
Less concerning ifNo change in cash flow guidance despite the earnings miss.
Why it matters: Improving cash flow is crucial for the company's financial health and future growth.
Supportive ifCash flow from operations turns positive in Q2.
Worry ifCash flow from operations remains negative in Q2.
Why it matters: A clear plan from management could indicate a turnaround strategy. Investors want to see action on reducing losses.
Supportive ifManagement has a clear plan. They want to lower net losses in the next earnings call.
Worry ifNo clear plan is presented to address net losses in the next earnings call.
Why it matters: This data will support the initiation of a pivotal study for XmAb819 in 2027.
Supportive ifPositive data from the expansion cohort will be shown at a medical conference in 2H26.
Worry ifNo data will be shown or there will be negative results from the expansion cohort study.
Why it matters: A decrease in net losses shows progress in managing costs, which is a key priority.
Supportive ifQ2 net losses decrease year over year by more than 10%.
Worry ifQ2 net losses increase year over year or stay the same.
Why it matters: This study is important for XmAb412. It targets inflammation in autoimmune diseases.
Supportive ifInitiation of the first-in-human study for XmAb412 in Q3 2026 as planned.
Worry ifDelay in starting the XmAb412 study beyond Q3 2026.
Why it matters: The results will show how XmAb819 works in treating clear cell renal cell carcinoma. Positive data could support future studies.
Supportive ifXmAb819 results at ESMO show good outcomes for advanced ccRCC patients.
Worry ifXmAb819 results at ESMO show poor outcomes or safety problems.
Why it matters: Updates on XmAb942 may show progress in treating ulcerative colitis. This could affect investor trust.
Supportive ifXencor shares good interim results for XmAb942 in the XENITH-UC study by year-end 2026.
Worry ifXencor reports delays or bad interim results for XmAb942 in the XENITH-UC study.
Why it matters: Initial data will show how well XmAb412 works and its safety. This could change future plans.
Supportive ifXencor has early data from the XmAb412 Phase 1 study. It shows good safety and effectiveness.
Worry ifEarly data from the XmAb412 Phase 1 study shows serious safety problems. It also shows no effectiveness.
Why it matters: This payment shows the end of the royalty dispute. It also helps Xencor's cash position.
Supportive ifXencor gets the first $52.5 million payment from Alexion as part of the settlement.
Worry ifXencor does not get the payment on time, showing possible issues with the settlement.